The Efficacy, Safety and Tolerability of Canakinumab in the Treatment of Familial Mediterranean Fever: A Systematic Review of the Literature
Mark Kacar,1 Sinisa Savic,1 Jeroen CH van der Hilst2,3 1Department of Clinical Immunology and Allergy, St James´s University Hospital, Leeds, UK; 2Department of Infectious Diseases and Immunity, Jessa Hospital, Hasselt, Belgium; 3BIOMED Research Institute, University of Hasselt, Hasselt, B...
Main Authors: | Kacar M, Savic S, van der Hilst JCH |
---|---|
Format: | Article |
Language: | English |
Published: |
Dove Medical Press
2020-03-01
|
Series: | Journal of Inflammation Research |
Subjects: | |
Online Access: | https://www.dovepress.com/the-efficacy-safety-and-tolerability-of-canakinumab-in-the-treatment-o-peer-reviewed-article-JIR |
Similar Items
-
Is it possible to extend the dose interval of canakinumab treatment in children with familial Mediterranean fever? PeRA group experience
by: Gülşah Kavrul Kayaalp, et al.
Published: (2023-11-01) -
Canakinumab in colchicine resistant familial Mediterranean fever and other pediatric rheumatic diseases
by: Mustafa Çakan, et al.
Published: (2020-04-01) -
Effectiveness of Canakinumab Treatment in Colchicine Resistant Familial Mediterranean Fever Cases
by: Burcu Bozkaya Yücel, et al.
Published: (2021-09-01) -
Assessment of effectiveness of anakinra and canakinumab in patients with colchicine-resistant/unresponsive familial Mediterranean fever
by: Ali Şahin, et al.
Published: (2020-01-01) -
Familial Mediterranean Fever: an unusual cause of liver disease
by: Maria Cristina Maggio, et al.
Published: (2019-09-01)